Marsha Jones

839 total citations
11 papers, 349 citations indexed

About

Marsha Jones is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Reproductive Medicine. According to data from OpenAlex, Marsha Jones has authored 11 papers receiving a total of 349 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Hematology, 3 papers in Public Health, Environmental and Occupational Health and 3 papers in Reproductive Medicine. Recurrent topics in Marsha Jones's work include Ovarian cancer diagnosis and treatment (3 papers), Chronic Myeloid Leukemia Treatments (3 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers). Marsha Jones is often cited by papers focused on Ovarian cancer diagnosis and treatment (3 papers), Chronic Myeloid Leukemia Treatments (3 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers). Marsha Jones collaborates with scholars based in United States, United Kingdom and Belgium. Marsha Jones's co-authors include Lisa Meng, Gail L. Brown, James Keck, Karl J. Crossen, Ignace Vergote, Azra Raza, Naomi Galili, Brad Rodu, John T. Carpenter and J. J. Kavanagh and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Marsha Jones

11 papers receiving 338 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marsha Jones United States 9 164 89 60 46 43 11 349
Yashiro Motooka Japan 10 160 1.0× 51 0.6× 27 0.5× 46 1.0× 20 0.5× 23 366
Agata Nowak Poland 12 108 0.7× 31 0.3× 21 0.3× 210 4.6× 40 0.9× 23 423
Huaijun Zhou China 14 291 1.8× 53 0.6× 88 1.5× 10 0.2× 26 0.6× 38 523
ME Sherman United States 5 116 0.7× 145 1.6× 81 1.4× 17 0.4× 37 0.9× 6 348
Shaoru Li China 11 239 1.5× 13 0.1× 81 1.4× 21 0.5× 14 0.3× 34 418
Xiujie Sheng China 10 292 1.8× 44 0.5× 61 1.0× 5 0.1× 28 0.7× 24 454
Vinodh R. Nannan Panday Netherlands 9 61 0.4× 35 0.4× 248 4.1× 27 0.6× 26 0.6× 16 334
C. Buicu Belgium 6 214 1.3× 67 0.8× 85 1.4× 4 0.1× 19 0.4× 9 463
Tianzhou Ma United States 8 135 0.8× 147 1.7× 177 3.0× 4 0.1× 31 0.7× 12 499
Yuko Takano Japan 12 122 0.7× 79 0.9× 134 2.2× 6 0.1× 96 2.2× 34 405

Countries citing papers authored by Marsha Jones

Since Specialization
Citations

This map shows the geographic impact of Marsha Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marsha Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marsha Jones more than expected).

Fields of papers citing papers by Marsha Jones

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marsha Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marsha Jones. The network helps show where Marsha Jones may publish in the future.

Co-authorship network of co-authors of Marsha Jones

This figure shows the co-authorship network connecting the top 25 collaborators of Marsha Jones. A scholar is included among the top collaborators of Marsha Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marsha Jones. Marsha Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Johnson, Melissa L., Tim Meyer, Daniel M. Halperin, et al.. (2018). First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): Phase 1 results.. Journal of Clinical Oncology. 36(15_suppl). 4097–4097. 19 indexed citations
2.
Crossen, Karl J., et al.. (2016). Radiofrequency septal reduction in symptomatic hypertrophic obstructive cardiomyopathy. Heart Rhythm. 13(9). 1885–1890. 30 indexed citations
3.
Vergote, Ignace, Neil J. Finkler, James B. Hall, et al.. (2010). Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer. International Journal of Gynecological Cancer. 20(5). 772–780. 47 indexed citations
4.
Kavanagh, John J., Charles F. Levenback, Pedro T. Ramírez, et al.. (2010). Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. Journal of Hematology & Oncology. 3(1). 9–9. 21 indexed citations
5.
6.
Sequist, Lecia V., Panos Fidias, Jennifer S. Temel, et al.. (2009). Phase 1-2a Multicenter Dose-Ranging Study of Canfosfamide in Combination with Carboplatin and Paclitaxel as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 4(11). 1389–1396. 18 indexed citations
7.
8.
Raza, Azra, Naomi Galili, Natalie S. Callander, et al.. (2009). Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra®, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. Journal of Hematology & Oncology. 2(1). 20–20. 49 indexed citations
9.
Raza, Azra, Naomi Galili, Scott E. Smith, et al.. (2009). Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. Blood. 113(26). 6533–6540. 54 indexed citations
10.
Raza, Azra, Naomi Galili, Scott E. Smith, et al.. (2007). Phase 1 Dose Escalation Study of TLK199 Tablets (Telintra), a Novel Glutathione Analog, in Myelodysplastic Syndrome.. Blood. 110(11). 1454–1454. 5 indexed citations
11.
Rodu, Brad, John T. Carpenter, & Marsha Jones. (1988). The pathogenesis and clinical significance of cytologically detectable oralCandida in acute leukemia. Cancer. 62(9). 2042–2046. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yashiro Motooka Breakdown of academic impact, for papers by Agata Nowak Breakdown of academic impact, for papers by Huaijun Zhou Breakdown of academic impact, for papers by ME Sherman Breakdown of academic impact, for papers by Shaoru Li Breakdown of academic impact, for papers by Xiujie Sheng Breakdown of academic impact, for papers by Vinodh R. Nannan Panday Breakdown of academic impact, for papers by C. Buicu Breakdown of academic impact, for papers by Tianzhou Ma Breakdown of academic impact, for papers by Yuko Takano
Rankless by CCL
2026